All In Biotech

Drug Trial Radar · NCT05472662

A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma

A Single-dose, Randomised, Double-blind, Controlled, 2-way Cross-over Study to Assess the Potential for Bronchoconstriction of the New Propellant HFA-152a Versus the Marketed HFA-134a Propellant, in Adult Subjects With Mild Asthma

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Aug 3, 2022

Primary completion

Oct 31, 2022

Study completion Oct 31, 2022

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Jul 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIa, multicentre, single dose, randomised, double blind, controlled, 2 way cross-over study to evaluate the potential for bronchoconstriction of the new HFA-152a propellant (single dose) versus the marketed HFA-134a propellant (single dose) in adults with mild asthma. HFA=Hydrofluoroalkane

Conditions

  • Asthma

Interventions

  • Placebo 152aDrug

    Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant

  • Placebo 134aDrug

    Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Relative Change From Baseline* in Forced Expiratory Volume in 1 s (FEV1) -- 15 Min Post-doseTime frame: At 15 min post-dose after T1.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medicine Evaluation Unit Limited

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.